USFDA Inspects AuroPeptides, Notes One Facility Maintenance Observation

The United States Food and Drug Administration (USFDA) has concluded its inspection of AuroPeptides, a manufacturer specializing in Peptide APIs and a key business arm of Aurobindo Pharma. This regulatory oversight resulted in the identification of a single observation concerning the facility and its equipment maintenance.

Details of the USFDA Observation

Crucially, the lone observation made by the USFDA does not relate to data integrity, a critical concern in pharmaceutical manufacturing. Furthermore, it does not pertain to other areas of Good Manufacturing Practice (GMP) compliance, indicating a specific focus on structural and operational upkeep rather than systemic quality control issues.

Inspection Schedule and Site

The USFDA team carried out their inspection activities at the AuroPeptides facility over five days, from August 17 to August 21, 2026. This manufacturing site is strategically located in Indrakaran Village, within the Sangareddy District of Telangana, India.

Aurobindo Pharma’s Extensive Portfolio

Aurobindo Pharma, the parent entity, maintains a broad operational scope within the pharmaceutical sector. The company is actively involved in the manufacturing of various pharmaceutical products, encompassing active pharmaceutical ingredients (APIs) and intermediates.

Its product portfolio includes generic formulations such as astemizole, domeperidone, and omeprazole, serving diverse medical needs. Additionally, Aurobindo Pharma has a strong presence in therapeutic segments like anti-infectives, oral and sterile antibiotics, pain management solutions, and treatments for osteoporosis.